Authors of this recent research discuss the functioning and classification of AI using melanoma as an example to build an understanding of the technology behind AI.
Studies reported in this review offer insight into how circulating biomarkers can have a role in personalized treatments for melanoma patients receiving ICIs therapy, emphasizing the need for rigorous clinical trials to confirm findings and establish standardized procedures.
A new position statement regarding balancing the risks and benefits of sun exposure for Australian adults provides sun exposure advice that explicitly recognises the differing needs of Australia’s diverse population.
Circulating tumor DNA (ctDNA) is a predictive and prognostic biomarker that may allow routine, real-time monitoring of melanoma disease status. Authors of this recent study surveyed 44 US physicians to understand their preferences and practice patterns for biomarker and ctDNA testing in their patients with melanoma. The study concludes that physicians consider ctDNA testing potentially valuable for clinical decision-making but cited concerns that should be addressed.
According to this article, we must weigh the absolute benefits of adjuvant systemic therapy in melanoma as a number needed to treat (NNT) and have agreement within society of what is an acceptable balance of NNT versus number needed to harm (NNH).
The aim of this recent study was to explore the acceptability and feasibility of implementing personalised melanoma risk assessment and tailored patient education and skin surveillance within routine clinical care. The study concludes that it is feasible and acceptable to patients and clinic staff to calculate and deliver personalised melanoma risk information and tailored surveillance as part of routine clinical care within dermatology clinics.
This review provides insights into current melanoma treatments and recent therapeutic advances.
Findings of this recent study suggest that patients with clinical stage I and II melanoma who smoked had a significantly increased risk of death due to melanoma. Smoking status should be assessed at time of melanoma diagnosis and may be considered a risk factor for disease progression.
According to this recent study, there are potential opportunities for improving skin cancer prevention activities in primary care. Ensuring ease of programme delivery, integration with early detection and availability of resources such as risk assessment tools are enablers to encourage and increase uptake of primary prevention behaviours in primary care, for both practitioners and patients.
This study aims to evaluate the impact of adjuvant anti-PD1 therapy on the health-related quality of life (HRQOL) of patients with resected stage III/IV melanoma. It concludes that a significant proportion of patients with resected stage III/IV melanoma who received adjuvant anti-PD1 experienced clinically significant declines in role, social and emotional functioning at 12 months compared to baseline. It highlights the HRQOL issues that may arise during adjuvant anti-PD1 therapy which may require supportive care intervention.